Sign Out
Pregnancy: Etoricoxib is contraindicated in women who are pregnant or who may become pregnant.
No data are available on the use of Etoricoxib in pregnant woman and the risk to the human fetus exposed to Etoricoxib is unknown. However, as with other medications inhibiting prostaglandin synthesis, Etoricoxib may cause uterine inertia and premature closure of the ductus arteriosus if used during the last trimester.
In animal studies, reproductive toxicity was shown. While Etoricoxib administration in rats at approximately 1.5 times the daily human dose based on exposure did not result in teratogenicity. A low incidence of cardiovascular malformations and increases in post implantation loss were observed in Etoricoxib-treated rabbits.
Breastfeeding: It is not known whether Etoricoxib is excreted in human milk. However, Etoricoxib is excreted into the milk of lactating rat. The use of Etoricoxib is contraindicated during lactation.
